Yayın:
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Sadeleştirilmiş öğe sayfası
dc.contributor.authorÜskent, Necdet
dc.contributor.authorBurak Bi̇lgi̇n
dc.contributor.authorNail Paksoy
dc.contributor.authorMuhammed Mustafa Atçı
dc.contributor.authorSeda Kahraman
dc.contributor.authorSaadettin Kılıçkap
dc.contributor.authorDeniz Can Güven
dc.contributor.authorMerve Keskinkılıç
dc.contributor.authorMurat Ayhan
dc.contributor.authorÖnder Eren
dc.contributor.authorFatma Nihan Akkoç Mustafayev
dc.contributor.authorŞebnem Yaman
dc.contributor.authorErtuğrul Bayram
dc.contributor.authorİsmail Ertürk
dc.contributor.authorErkan Özcan
dc.contributor.authorMustafa Korkmaz
dc.contributor.authorBaran Akagündüz
dc.contributor.authorDi̇lek Erdem
dc.contributor.authorTuğba Akın Telli
dc.contributor.authorAsude Aksoy
dc.contributor.authorNecdet Üskent
dc.contributor.authorNaziyet Köse Baytemür
dc.contributor.authorAhmet Gülmez
dc.contributor.authorDinçer Aydın
dc.contributor.authorTeoman Şakalar
dc.contributor.authorHacı Arak
dc.contributor.authorAli Murat Tatlı
dc.contributor.authorYakup Ergün
dc.contributor.authorNaziye Ak
dc.contributor.authorÇağlar Ünal
dc.contributor.authorMehmet Alpaslan Özgün
dc.contributor.authorBülent Yalçın
dc.contributor.authorİlhan Öztop
dc.contributor.authorEfnan Algın
dc.contributor.authorAbdullah Sakin
dc.contributor.authorAdnan Aydıner
dc.contributor.authorPerran Fulden Yumuk
dc.contributor.authorMehmet Alı Nahıt Şendur
dc.contributor.orcid0000-0001-5147-4431
dc.contributor.orcid0000-0003-1717-8246
dc.contributor.orcid0000-0003-4636-2595
dc.contributor.orcid0000-0002-1300-3695
dc.contributor.orcid0000-0002-5328-6554
dc.contributor.orcid0000-0003-1637-7390
dc.contributor.orcid0000-0002-6924-9467
dc.contributor.orcid0000-0002-3342-3144
dc.contributor.orcid0000-0002-0631-4006
dc.contributor.orcid0000-0001-7024-4156
dc.contributor.orcid0000-0001-8713-7613
dc.contributor.orcid0000-0001-6835-0988
dc.contributor.orcid0000-0003-1562-6340
dc.contributor.orcid0000-0003-0926-6748
dc.contributor.orcid0000-0002-4979-3123
dc.contributor.orcid0000-0001-6495-6712
dc.contributor.orcid0000-0001-6535-6030
dc.contributor.orcid0000-0002-5609-9658
dc.contributor.orcid0000-0003-2739-7362
dc.contributor.orcid0000-0002-3587-2517
dc.contributor.orcid0000-0002-3353-344X
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0002-2023-423X
dc.contributor.orcid0000-0001-9696-1102
dc.contributor.orcid0000-0003-4784-6743
dc.contributor.orcid0000-0001-5790-7066
dc.contributor.orcid0000-0003-3245-1570
dc.contributor.orcid0000-0002-4431-8948
dc.contributor.orcid0000-0002-0425-0651
dc.contributor.orcid0000-0002-8917-9267
dc.contributor.orcid0000-0003-2538-8569
dc.contributor.orcid0000-0002-1104-5840
dc.contributor.orcid0000-0001-8650-299X
dc.contributor.orcid0000-0001-7021-6139
dc.date.accessioned2025-11-13T10:59:57Z
dc.date.issued2022-09-01
dc.identifier.doihttps://doi.org/10.1007/s00432-022-04252-2
dc.identifier.endpage4148
dc.identifier.issn0171-5216
dc.identifier.issue8
dc.identifier.openalexW4294031535
dc.identifier.startpage4141
dc.identifier.urihttps://hdl.handle.net/11421/5908
dc.identifier.urihttps://doi.org/10.1007/s00432-022-04252-2
dc.identifier.volume149
dc.language.isoen
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology
dc.rightsopenAccess
dc.subjectAlectinib
dc.subjectCrizotinib
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectALK inhibitor
dc.subjectLung cancer
dc.subjectTyrosine-kinase inhibitor
dc.subjectHematology
dc.subjectAnaplastic lymphoma kinase
dc.subjectGastroenterology
dc.subjectCancer
dc.subject.sdg3
dc.titleThe percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5064757657

Dosyalar

Koleksiyonlar

Publications